Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), based in Las Vegas, announced a significant advancement in obesity treatment. The company has filed a provisional patent for formulations using its Invisicare® technology for transdermal drug delivery. This patent, titled "Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery," aims to enhance the administration of obesity drugs.

The Invisicare® technology incorporates CB-1 receptor antagonists and GLP-1 receptor agonists into a topical lotion delivered via a metered applicator. Studies show up to a tenfold increase in transdermal delivery effectiveness using Invisicare®. This method aims to improve drug efficacy, reduce side effects, and offer a convenient alternative to oral or injectable therapies.

The global obesity drug market is expected to surpass $30 billion by 2027. Skinvisible's transdermal technology could overcome barriers posed by needles and injections, unlocking the potential of CB-1 and GLP-1 targeting drugs for broader patient access and adherence.

Terry Howlett, CEO of Skinvisible, stated, "Our transdermal technology could revolutionize obesity drug administration, enhancing treatment adherence and accessibility." Skinvisible is seeking partnerships to bring the first transdermal obesity therapies to market and explore other applications of its delivery platform.